Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Matthew S Davids; Michael Hallek; William Wierda; Andrew W Roberts; Stephan Stilgenbauer; Jeffrey A Jones; John F Gerecitano; Su Young Kim; Jalaja Potluri; Todd Busman; Andrea Best; Maria E Verdugo; Elisa Cerri; Monali Desai; Peter Hillmen; John F Seymour

Journal article

Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia

Matthew S Davids, Michael Hallek, William Wierda, Andrew W Roberts, Stephan Stilgenbauer, Jeffrey A Jones, John F Gerecitano, Su Young Kim, Jalaja Potluri, Todd Busman, Andrea Best, Maria E Verdugo, Elisa Cerri, Monali Desai, Peter Hillmen, John F Seymour

Clinical Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2018

DOI: 10.1158/1078-0432.CCR-17-3761

University of Melbourne Researchers

John Seymour Author Medicine - St Vincent's Hospital

Andrew Roberts Author

Grants

Funding Acknowledgements

We would like to thank the patients and their families, study investigators, study coordinators, and support staff. Medical writing support was provided by Sharanya Ford, PhD, data-programming support was provided by Joseph Beason, and additional scientific support was provided by Cynthia Bartkus and Adrienne Rothstein; all are employees of AbbVie. Venetoclax is being developed in collaboration between AbbVie and Genentech. AbbVie and Genentech provided financial support for the studies and participated in the design, study conduct, analysis and interpretation of data, as well as the writing, review, and approval of the manuscript. Funding for the studies included in this analysis was provided by AbbVie Inc. and Genentech Inc.